TOP NEWS: Astra transfers drug rights to Covis in USD270 million deal
TOP NEWS: Astra transfers drug rights to Covis in USD270 million deal
Read moreFri, 03rd Dec 2021 13:23
TOP NEWS: Astra transfers drug rights to Covis in USD270 million deal
Read moreIN BRIEF: Hutchmed begins phase 3 trial of thrombocytopenia drug
Read moreHutchmed China sells joint venture stake for USD169 million
Read moreHutchmed starts drug combination trial for neuroendocrine tumours
Read moreHutchmed starts Japan trial for surufatinib in neuroendocrine tumors
Read moreHutchmed China's amdizalisib secures breakthrough therapy designation
Read moreHutchmed, Astra launch drug combination trial to treat lung cancer
Read moreHutchmed China to trade in Shanghai and Shenzhen through link scheme
Read moreHutchmed launches trial into drug combination to treat breast cancer
Read more(Sharecast News) - Commercial-stage biotechnology company Hutchmed China announced a collaboration to research, develop, manufacture and commercialise 'Tazverik' in Greater China on Monday, including mainland China, Hong Kong, Macau and Taiwan.
Read moreHutchmed to partner with Epizyme on tumour-targetting treatment
Read moreHutchmed research costs deepen loss; expects US launches in 2022, 2023
Read moreIN BRIEF: Hutchmed and AstraZeneca launch phase two cancer med trial
Read moreAIM WINNERS & LOSERS: Hutchmed notes phase 2 trial; Tricorn drops 25%
Read moreUK earnings, trading statements calendar - next 7 days
Read more